SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Iovance Biotherapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of cell therapies as novel cancer immunotherapy products. Its lead product candidate, LN-144 for metastatic melanoma, is an autologous adoptive cell therapy utilizing tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients' tumors. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.

Iovance Biotherapeutics Inc

Iovance Biotherapeutics is capturing significant market attention as it holds above key support levels following recent earnings, with investors closely monitoring a massive short interest that could fuel a rapid move higher if bullish clinical catalysts materialize. The community is heavily focused on the company's expanding oncology platform and the potential for a breakthrough in non-small cell lung cancer, viewing these developments as the primary drivers that could trigger a significant re-rating.

Unusual Machines, Inc. is a development stage technology company, which engages in the provision of drone solutions with a focus on first-person view (FPV) technology. It offers products to entertainment, recreation, and competitive racing industries. The company was founded on July 11, 2019, and is headquartered in Orlando, FL.

Unusual Machines Inc

Unusual Machines is surging as investors react to a major government policy catalyst involving new tariffs on foreign-made drones, positioning the company as a key domestic infrastructure play within the defense sector. The community remains hyper-focused on its high short interest and potential for a significant squeeze, while debating the long-term impact of its manufacturing capacity and strategic industry ties.

XRP is a decentralized digital asset and the native token of the XRP Ledger, a Layer 1 blockchain designed for high-performance global payments. Its primary value proposition is offering a fast, cost-effective alternative to traditional banking systems by enabling near-instant cross-border settlements that finalize in three to five seconds. By serving as a neutral bridge asset between different fiat currencies, it helps financial institutions lower liquidity costs and eliminates the need for pre-funded accounts.  The network is unique because it utilizes a federated consensus protocol instead of energy-intensive mining or staking. This system achieves deterministic finality through a Unique Node List of trusted validators who must reach an eighty percent agreement threshold to permanently record transactions. This infrastructure supports a sustained throughput of 1,500 transactions per second and includes a built-in decentralized exchange that allows for the automated trading of any tokenized asset without intermediaries.  The project traces its origins back to 2004 with Ryan Fugger before being co-founded in its modern form by Jed McCaleb and Chris Larsen. The company, now known as Ripple, works with major financial institutions as partners and investors to build global payment solutions. To protect the network from spam, a small amount of XRP is burned during every transaction, and the token is further utilized by institutions as collateral to access traditional markets and manage digital asset infrastructure.  Institutional adoption of the asset reached a major milestone in November 2025 when the SEC approved the first wave of spot XRP ETFs. These products, offered by major issuers including Bitwise, Grayscale, 21Shares, Canary Capital, and Franklin Templeton, are now listed on prominent exchanges like the NYSE Arca, Nasdaq, and Cboe BZX. While Ripple remains a key contributor to the ecosystem, the underlying XRP Ledger continues to operate as an open-source and decentralized network.

Ripple

Ripple's XRP is trending as community members express intense polarization, with some panic-selling or labeling the token a "scam" while others view the recent dip below the psychological one-dollar support level as a prime long-term accumulation opportunity. Discussions are heavily focused on regulatory uncertainty, skepticism toward the Clarity Act, and frustration regarding potential coin dilution, leaving the investor base deeply divided between those abandoning ship and those doubling down on the asset's long-term utility narrative.

New Era Energy & Digital, Inc. is an exploration and production company, which engages in selling oil and natural gas products. The company was founded on February 6, 2023 and is headquartered in Midland, TX.

New Era Energy & Digital Inc.

New Era Energy & Digital Inc. is trending as investors weigh significant project de-risking milestones, including secured construction permits for its Texas data center site, against concerns over widened losses and share dilution. The community remains sharply divided, with bulls pointing to institutional accumulation and long-term infrastructure potential, while bears focus on the lack of a finalized tenant contract and high cash burn.

Albemarle Corp. engages in the development, manufacture, and marketing of chemicals for consumer electronics, petroleum refining, utilities, packaging, construction, transportation, pharmaceuticals, crop production, food-safety, and custom chemistry services. It operates through the following segments: Energy Storage, Specialties, and Ketjen. The Energy Storage segment develops and manufactures a broad range of basic lithium compounds, including lithium carbonate, lithium hydroxide, and lithium chloride. The Specialties segment focuses on optimizing a portfolio of bromine and specialized lithium solutions. The Ketjen segment consists of clean fuels technologies, fluidized catalytic cracking catalysts and additives, and performance catalyst solutions, which is primarily composed of organometallics and curatives. The company was founded in 1993 and is headquartered in Charlotte, NC.

Albemarle Corp.

Albemarle Corp

Albemarle is experiencing heightened market interest driven by a combination of institutional call sweep activity, strategic debt reduction efforts, and an improving lithium demand outlook fueled by grid-scale storage and the AI infrastructure boom. The community remains focused on recent institutional accumulation and optimistic guidance revisions, even as the stock consolidates following a rapid price surge.

EyePoint, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics that treat eye disorders. It offers FDA-approved sustained-release treatments in ophthalmology under the DEXYCU, ILUVIEN, Verisome, Retisert, and Durasert brands. The company was founded in 1987 and is headquartered in Watertown, MA.

EyePoint Inc.

EyePoint Pharmaceuticals Inc

EyePoint Pharmaceuticals is seeing heavy volatility as traders debate the company's upcoming Phase 3 trial data, with significant activity in put options signaling potential hedging against binary event risks. Community discourse remains divided between those anticipating a clinical breakthrough that could spark a major move and skeptics closely watching high short interest and competitor trial designs.

Tidal Trust II - Defiance Daily Target 2x Long MSTR ETF

Defiance Daily Target 2x Long MSTR ETF

MSTX is trending as investors debate the impact of significant volatility and a scheduled reverse split on the leveraged ETF's performance. Community sentiment is deeply polarized, with many traders looking to capitalize on extreme oversold levels while others warn of the risks inherent in holding leveraged instruments long-term.

BitGo Holdings, Inc. operates as a digital asset infrastructure company delivering custody, wallets, staking, trading, financing, stablecoins, and settlement services from regulated cold storage. It focuses on accelerating the transition of the financial system to a digital asset economy. The company was founded by Michael Belshe and Ben Davenport in 2013 and is headquartered in Sioux Falls, SD.

BitGo Holdings Inc. - Ordinary Shares - Class A

BitGo Holdings is facing intense community debate as the stock navigates a volatile post-IPO period, with bullish investors highlighting a newly approved $50 million buyback and the company's role as a federally regulated custodian while skeptics point to disappointing earnings and technical selling pressure. Discussion is heavily split between those anticipating a major short squeeze driven by heavy institutional interest and those warning of further downside due to macro headwinds and the company's competitive landscape.

Upwork, Inc. is an online marketplace which engages in the provision of businesses to find, hire, and pay freelancers for short-term and longer-term projects. Its marketplace offerings include Upwork Basic, Upwork Plus, Upwork Business, Upwork Enterprise, and Upwork Payroll. The company was founded by Odysseas Tsatalos and Efstratios Karamanlakis in December 2013 and is headquartered in Palo Alto, CA.

Upwork Inc

Upwork is trending as market participants debate its long-term viability amid rapid AI advancements, with many investors highlighting its strong cash flow and aggressive share buyback programs as evidence of deep value. Meanwhile, the community remains divided between those positioning for a potential short squeeze due to high short interest and those expressing concern over competitive pressures from automated AI tools.

Chainlink is the industry-standard decentralized oracle network that solves the "oracle problem" by connecting smart contracts with real-world data. Blockchains cannot access external information on their own, so Chainlink acts as a secure bridge, enabling smart contracts to react to real-world events using verified, tamper-proof data. It is widely considered one of the first decentralized oracle networks and is the market leader in bringing off-chain data on-chain.  The platform operates through a decentralized network of nodes that fetch, validate, and deliver data to smart contracts. When a contract requests information like a stock price, a committee of independent nodes retrieves and aggregates the data to reach consensus, then delivers a single trustworthy answer. Chainlink offers a suite of services including Data Feeds for asset prices, CCIP for cross-chain token transfers and messaging, Automation for triggering smart contract functions, and Proof of Reserve for verifying asset collateralization.  Chainlink has established itself as critical infrastructure for both DeFi and institutional adoption, with partnerships including Swift, Euroclear, Mastercard, UBS, ANZ, Fidelity International, and J.P. Morgan. Its institutional products include the Chainlink Runtime Environment for tokenized asset workflows, Confidential Compute for privacy-preserving computation, and the Automated Compliance Engine for embedding regulatory rules into smart contracts.  The LINK token is the native asset used to pay node operators for services, fund subscription accounts, and incentivize network security through staking. Node operators stake LINK as collateral, which can be slashed if they provide inaccurate data. Chainlink was co-founded in 2017 by Sergey Nazarov and Steve Ellis, who co-authored the white paper with Ari Juels, and raised $32 million in its September 2017 ICO.

ChainLink

Chainlink is seeing increased investor focus as the community speculates on its role as essential infrastructure for real-world asset tokenization and institutional adoption, with many active discussions centered on upcoming regulatory clarity and the potential for a long-term breakout. Traders are closely monitoring the token's ability to maintain support levels while debating whether recent partnerships and technical developments will finally catalyze a move toward higher resistance.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

PTC Therapeutics Expands Rare Disease Portfolio with 'Unique Opportunity'

PTC Therapeutics plans to acquire Sangamo's ST-920 Fabry disease program for $111 million upfront, with FDA filing expected in Q4 2026.read more...

PTC to Expand Rare Disease Portfolio with Acquisition of BLA-Stage ST-920 Fabry Disease Program

PTC to Expand Rare Disease Portfolio with Acquisition of BLA-Stage ST-920 Fabry Disease Program PTC to Expand Rare Disease Portfolio with Acquisition of BLA-Stage ST-920 Fabry Disease Program PR Newswire WARREN, N.J., Aug. 12, 2026 Planned acquisition leverages existing regulatory and commercial...

PTC Therapeutics (PTCT) Loses 20.3% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

PTC Therapeutics (PTCT) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

PTC Therapeutics (PTCT) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

Although the revenue and EPS for PTC Therapeutics (PTCT) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

PTC Therapeutics (PTCT) Beats Q2 Earnings and Revenue Estimates

PTC Therapeutics (PTCT) delivered earnings and revenue surprises of +641.18% and +22.24%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

PTC Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results

PTC Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results PTC Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results PR Newswire WARREN, N.J., July 30, 2026 Robust Q2 performance with total revenue of $361 million, including $239...

Analysts Estimate BioMarin Pharmaceutical (BMRN) to Report a Decline in Earnings: What to Look Out for

BioMarin (BMRN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will PTC Therapeutics (PTCT) Report Negative Earnings Next Week? What You Should Know

PTC Therapeutics (PTCT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Hamilton Lane Board Elects Michael Schmertzler as New Independent Director

Hamilton Lane Board Elects Michael Schmertzler as New Independent Director Hamilton Lane Board Elects Michael Schmertzler as New Independent Director PR Newswire CONSHOHOCKEN, Pa., July 23, 2026 CONSHOHOCKEN, Pa., July 23, 2026 /PRNewswire/ -- Leading private markets investment management firm...

uniQure Trends to Watch as Gene Therapy Bets Shift Beyond Hemgenix

QURE is sharpening its gene therapy focus through faster regulatory pathways, a streamlined business model and CNS pipeline expansion, with AMT-130 at the center.

PTC Therapeutics, Inc. is a biopharmaceutical company, which focuses on the discovery, development, and commercialization of clinically differentiated medicines that provide benefits to patients with rare disorders. The company was founded by Allan Steven Jacobson and Stuart Walter Peltz on March 31, 1998 and is headquartered in Warren, NJ.

PTC Therapeutics Inc

PTC Therapeutics Stock In The Spotlight After FDA Refuses Approval For Drug To Treat Neurodegenerative Disease, Analysts Are Divided

Equity

Bullish Sentiment

Up more than 1% 

Flat to up 1%

Flat to down 1%

Down more than 1%

The S&P 500 ($SPY) is headed towards a winning week. What do you think the index's return will look like next week? Vote and explain your reasoning in the comments.

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Feed

News

Sentiment

Earnings

Fundamentals

Info

PTCTPTC Therapeutics Inc

Fundamentals

Connect Stocktwits to ChatGPT

Latest PTCT News